-
EP2813504
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2813504
| EP2813504 - 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 27.11.2015 Database last updated on 14.11.2024 | Most recent event Tooltip | 27.11.2015 | Application deemed to be withdrawn | published on 30.12.2015 [2015/53] | Applicant(s) | For all designated states Institut Quimic De Sarriá Cets, Fundació Privada Vía Augusta 390 08017 Barcelona / ES | For all designated states Hospital Clínic de Barcelona C/ Villaroel, 170 08036 Barcelona / ES | For all designated states Fundacio Clinic Per A La Recerca Biomedica C / Rossello 149-153 08036 Barcelona / ES | For all designated states Institut d'Investigacions Biomédiques August Pi i Sunyer C/ Rosselló, 149-153 08036 Barcelona / ES | [2014/51] | Inventor(s) | 01 /
Borrell Bilbao, José Ignacio INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA Via Augusta, 390 E-08017 Barcelona / ES | 02 /
Teixido Closa, Jordi INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA Via Augusta, 390 E-08017 Barcelona / ES | 03 /
Puig De La Bellacasa Cazorla, Raimon INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA Via Augusta, 390 E-08017 Barcelona / ES | 04 /
Colomer Pujol, Dolors HOSPITAL CLÍNIC DE BARCELONA Villarroel, 170 E-08036 Barcelona / ES | 05 /
Roue, Gael FUNDACIÓ CLINIC PER A LA RECERCA BIOMÈDICA (FCRB) Rosselló, 149-153 E-08036 Barcelona / ES | 06 /
Pérez Galán, Patricia INSTITUT D ́INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER Rosselló, 149-153 E-08036 Barcelona / ES | [2014/51] | Representative(s) | ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES | [N/P] |
| Former [2014/51] | ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES | Application number, filing date | 13382225.4 | 14.06.2013 | [2014/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2813504 | Date: | 17.12.2014 | Language: | EN | [2014/51] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.10.2013 | Classification | IPC: | C07D471/04, A61K31/519, A61P35/00 | [2014/51] | CPC: |
C07D471/04 (EP,US);
A61K31/136 (US);
A61K31/395 (EP,US);
A61K31/435 (US);
A61K31/4353 (US);
A61K31/4375 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/51] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate, Synthese und Verwendungen davon | [2014/51] | English: | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | [2014/51] | French: | 4-Amino-6-(2,6-dichlorophényl)-2-(phénylamino)-pyrido [2,3-d]pyrimidin-7(8h)-one, leur synthèse et leurs utilisations | [2014/51] | Examination procedure | 14.06.2013 | Examination requested [2014/51] | 18.06.2015 | Application deemed to be withdrawn, date of legal effect [2015/53] | 27.07.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2015/53] | Fees paid | Penalty fee | Additional fee for renewal fee | 30.06.2015 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2004063195 (SLOAN KETTERING INST CANCER [US], et al) [A] 1-15 * Claims; page 3, lines 8-11; page 48, lines 22-30; page 63, line 27 to page 64, line 19; page 78, table 1; page 84, lines 20-31. *; | [A]US2009312321 (REN PINGDA [US], et al) [A] 1-15 * Abstract; claims; examples; pages 12-15, section "pharmacology and utility", particularly paragraphs 0107, 0109, 0130-0131, 0135. *; | [A]US2009062274 (BAIK TAE-GON [US], et al) [A] 1-15 * Paragraphs 0011-0021; pages 15-29, table 1: examples; paragraph 0109: non-Hodgkin's lymphoma. *; | [A]WO2012028756 (INST QUIMIC DE SARRIA CETS FUNDACIO PRIVADA [ES], et al) [A] 1-15 * Abstract; page 1, line 23 to page 2, line 2; page 3, lines 12-16; claims; page 19, lines 12-33: example of formula 3. *; | [A]US2013116262 (CRAWFORD JAMES JOHN [US], et al) [A] 1-15 * Abstract; claims 1, 18, 22; examples. *; | [A] - KLUTCHKO ET AL., "2-SUBSTITUTED AMINOPYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONES. STRUCTURE-ACTIVITY RELATIONSHIPS AGAINST SELECTED TYROSINE KINASES AND IN VITRO AND IN VIVO ANTICANCER ACTIVITY", J. MED. CHEM., (19980101), vol. 41, no. 17, doi:10.1021/JM9802259, ISSN 0022-2623, pages 3276 - 3292, XP002191992 [A] 1-15 * Title; abstract; tables 1-3. * DOI: http://dx.doi.org/10.1021/jm9802259 | [A] - ANTCZAK ET AL., "Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors", BIOORG. MED. CHEM. LETT., vol. 19, no. 24, doi:10.1016/J.BMCL.2009.10.085, ISSN 0960-894X, (20091215), pages 6872 - 6876, (20091023), XP026754138 [A] 1-15 * Title; abstract; tables 1-4. * DOI: http://dx.doi.org/10.1016/j.bmcl.2009.10.085 | [A] - YAN ET AL., "Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies", J. MED. CHEM., (20120306), vol. 55, no. 10, doi:10.1021/jm300035p, ISSN 0022-2623, pages 4539 - 4550, XP055080230 [A] 1-15 * The whole document. In particular "introduction" and page 4540, table 1: compounds 6, 7. * DOI: http://dx.doi.org/10.1021/jm300035p | by applicant | US3702889 | - NOGAI H; DORKEN B; LENZ G, "Pathogenesis of non-Hodgkin's lymphoma", J. CLIN. ONCOL., (2011), vol. 29, no. 14, pages 1803 - 1811 | - ZENZ T; MERTENS D; KUPPERS R ET AL., "From pathogenesis to treatment of chronic lymphocytic leukaemia", NAT. REV. CANCER, (2010), vol. 10, no. 1, pages 37 - 50 | - JARES P; COLOMER D; CAMPO E, "Molecular pathogenesis of mantle cell lymphoma", J. CLIN. INVEST., (201201), vol. 122, no. 10, pages 3416 - 23 | - KRIDEL R; SEHN LH; GASCOYNE RD, "Pathogenesis of follicular lymphoma", J. CLIN. INVEST., (2012), vol. 122, no. 10, pages 3424 - 3431 | - H. TILLY; M. DREYLING, "Diffuse large B-cell non- Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", ANN. ONCOL., (2010), vol. 21, no. 5, pages V172 - V174 | - MCCAIG AM; COSIMO E; LEACH MT; MICHIE AM, "Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals", BR. J. HAEMATOL., (2011), vol. 1 53, no. 2, pages 199 - 211 | - L6PEZ-GUERRA M; XARGAY-TORRENT S; PÉREZ-GALÁN P; SABORIT-VILLARROYA I; ROSICH L; VILLAMOR N; AYMERICH M; ROUE G; CAMPO E; MONTSE, "Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells", LEUKEMIA, (2012), vol. 2 6, no. 6, pages 1429 - 32 | - AMRIEN; AMREIN PC; ATTAR EC; TAKVORIAN T ET AL., "Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia", CLIN CANCER RES, (2011), vol. 17, pages 2977 - 86 | - AI-AMERI AM; BADOUX X; FERRAJOLI A ET AL., "Phase II study of dasatinib in patients with relapsed chronic lymphocytic leukemia", BLOOD, (2010), vol. 116, page 4488 | - ROBAK T; ROBAK E, "Tyrosine kinase inhibitors as potential drugs for B-celllymphoid malignancies and autoimmune disorders", EXPERT OPIN INVESTIG DRUGS, (201207), vol. 21, no. 7, pages 921 - 47 | - FRIEDBERG JW; SHARMAN J; SWEETENHAM J ET AL., "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin's lymphoma and chronic lymphocytic leukemia", BLOOD, (2010), vol. 115, no. 13, pages 2578 - 2585 | - HOELLENRIEGEL J; COFFEY GP; SINHA U ET AL., "Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration", LEUKEMIA, (2012), vol. 26, no. 7, pages 1576 - 1583 | - O'BRIEN S; BURGER JA; BLUM KA ET AL., "The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a Phase Ib/II study", BLOOD (ASH ANNUAL MEETING ABSTRACTS, (2011), vol. 118, no. 21, page 983 | - BYRD J, BLOOD, (2012), vol. 120, page 21 | - FOWLER NH, BLOOD, (2012), vol. 120, page 21 | - WILSON WH, BLOOD, (2012), vol. 120, page 21 | - PEREZ-PI, I.; BERZOSA, X.; GALVE, I.; TEIXIDO, J.; BORRELL, J. I., HETEROCYCLES, (2010), vol. 82, pages 581 - 591 | - HETEROCYCLES, (2010), vol. 82, pages 581 - 591 | - GALVE, I.; PUIG DE LA BELLACASA, R.; SANCHEZ-GARCIA, D.; BATLLORI, X.; TEIXIDO, J.; BORRELL, J. I., MOL. DIVER., (2012), vol. 16, pages 639 - 649 | - GALVE, I.; PUIG DE LA BELLACASA, R.; SANCHEZ- GARCIA, D.; BATLLORI, X.; TEIXIDO, J.; BORRELL, J. I., MOL. DIVER., (2012), vol. 16, pages 639 - 649 | - P. VICTORY; A. CRESPO; R. NOMEN; J. I. BORRELL, AFINIDAD, (1989), vol. 46, page 107 | - J. ATTENBURROW, J. CHEM. SOC. PERKIN TRANS. I, (1952), page 1104 | - FILIPSKI, K.J.; KOHRT, J.T.; CASIMIRO- GARCIA, A.; VAN HUIS, C.A.; DUDLEY, D.A.; CODY, W.L.; BIGGE, C.F.; DESIRAJU, S.; SUN, S.; M, TET. LETT., (2006), vol. 47, pages 7677 - 7680 | - J. KIM; S. CHANG, CHEM. COMMUN., (2008), pages 3052 - 3054 | - GALVE ET AL., MOL. DIVER., (2012), vol. 16, pages 639 - 649 | - ZHANG ET AL., J. BIOMOL. SCREEN., (1999), vol. 2, pages 67 - 73 | - IVERSEN ET AL., J. BIOMOL. SCREEN., (2006), vol. 3, pages 247 - 252 |